{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:06:27Z","timestamp":1780351587075,"version":"3.54.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T00:00:00Z","timestamp":1557532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>One year of adjuvant trastuzumab in combination with chemotherapy is the standard of care in early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Existing data on shortening trastuzumab treatment show conflicting results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A search of PubMed and abstracts from key conferences identified randomized trials that compared abbreviated trastuzumab therapy to 1 year of treatment in early-stage HER2-positive breast cancer. Hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted for disease-free survival (DFS) and overall survival (OS). Subgroup analyses evaluated the effect of nodal involvement, estrogen receptor expression, and the duration of abbreviated trastuzumab (9\u201312\u2009weeks vs 6\u2009months). Odds ratios (ORs) and 95% confidence intervals were computed for prespecified cardiotoxicity events including cardiac dysfunction and congestive heart failure. P values were two-sided.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Analysis included six trials comprising 11 603 patients. Shorter trastuzumab treatment was associated with worse DFS (HR\u2009=\u20091.14, 95% CI = 1.05 to 1.25, P \u2009=\u2009.002) and OS (HR\u2009=\u20091.15, 95% CI = 1.02 to 1.29. P\u2009=\u2009.02). The effect on DFS was not influenced by estrogen receptor status (P for the subgroup difference\u2009=\u2009.23), nodal involvement (P\u2009=\u2009.44), or the different duration of trastuzumab in the experimental arm (P\u2009=\u2009.09). Shorter trastuzumab treatment was associated with lower odds of cardiac dysfunction (OR\u2009=\u20090.67, 95% CI = 0.55 to 0.81, P\u2009&lt;\u2009.001) and congestive heart failure (OR\u2009=\u20090.66, 95% CI = 0.50 to 0.86, P\u2009=\u2009.003).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Compared with 1 year, shorter duration of adjuvant trastuzumab is associated with statistically significantly worse DFS and OS despite favorable cardiotoxicity profile. One year of targeted HER2 treatment should remain the standard adjuvant treatment in early-stage HER2-positive disease with appropriate cardiac monitoring.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jncics\/pkz033","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T21:18:19Z","timestamp":1556572699000},"source":"Crossref","is-referenced-by-count":17,"title":["Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis"],"prefix":"10.1093","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9557-4634","authenticated-orcid":false,"given":"Hadar","family":"Goldvaser","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, University of Toronto and Princess Margaret Cancer Centre, Toronto, Canada"},{"name":"Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Korzets","sequence":"additional","affiliation":[{"name":"Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Israel"},{"name":"Department of Radiation Oncology, University of Toronto and Princess Margaret Cancer Centre, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Shepshelovich","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of Toronto and Princess Margaret Cancer Centre, Toronto, Canada"},{"name":"Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinat","family":"Yerushalmi","sequence":"additional","affiliation":[{"name":"Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Sarfaty","sequence":"additional","affiliation":[{"name":"Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domen","family":"Ribnikar","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of Toronto and Princess Margaret Cancer Centre, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paaladinesh","family":"Thavendiranathan","sequence":"additional","affiliation":[{"name":"Ted Rogers Program in Cardiotoxicity Prevention, Toronto General Hospital, Peter Munk Cardiac Center, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3706-525X","authenticated-orcid":false,"given":"Eitan","family":"Amir","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of Toronto and Princess Margaret Cancer Centre, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,11]]},"reference":[{"issue":"10087","key":"2019070511331770000_pkz033-B1","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"issue":"14","key":"2019070511331770000_pkz033-B2","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"issue":"33","key":"2019070511331770000_pkz033-B3","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10075","key":"2019070511331770000_pkz033-B4","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"2019070511331770000_pkz033-B5","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/annonc\/mdx308","article-title":"De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017","volume":"28","author":"Curigliano","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"2019070511331770000_pkz033-B6","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1016\/j.breast.2013.07.029","article-title":"Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies","volume":"22","author":"Pinto","year":"2013","journal-title":"Breast"},{"issue":"5","key":"2019070511331770000_pkz033-B7","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1634\/theoncologist.2015-0424","article-title":"Risk of congestive heart failure in early breast cancer patients undergoing adjuvant treatment with trastuzumab: a meta-analysis","volume":"21","author":"Long","year":"2016","journal-title":"Oncologist"},{"issue":"20","key":"2019070511331770000_pkz033-B8","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2013.53.9288","article-title":"Trastuzumab associated cardiac events at 8 years of median follow-up in the Herceptin adjuvant trial (BIG 1-01)","volume":"32","author":"de Azambuja","year":"2014","journal-title":"J Clin Oncol"},{"key":"2019070511331770000_pkz033-B9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ctrv.2017.08.001","article-title":"Duration of adjuvant trastuzumab in HER2 positive breast cancer: overall and disease free survival results from meta-analyses of randomized controled trials","volume":"60","author":"Gyawali","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"2019070511331770000_pkz033-B10","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2006.06.3081","article-title":"A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2\/neu-positive breast cancer","volume":"25","author":"Kurian","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019070511331770000_pkz033-B11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa053028","article-title":"Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer","volume":"354","author":"Joensuu","year":"2006","journal-title":"N Engl J Med"},{"issue":"34","key":"2019070511331770000_pkz033-B12","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1200\/JCO.2008.21.4577","article-title":"Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial","volume":"27","author":"Joensuu","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019070511331770000_pkz033-B13","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/annonc\/mdv213","article-title":"Six versus 12\u00a0months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)","volume":"26","author":"Mavroudis","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"2019070511331770000_pkz033-B14","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1470-2045(13)70225-0","article-title":"Six months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol"},{"key":"2019070511331770000_pkz033-B15","article-title":"9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: results of the phase III multicentric Italian study Short-HER","volume":"35(suppl; abstr 501)","author":"Conte","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019070511331770000_pkz033-B16","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1001\/jamaoncol.2018.1380","article-title":"Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2\u2013positive breast cancer the SOLD randomized clinical trial","volume":"4","author":"Joensuu","year":"2018","journal-title":"JAMA Oncol"},{"key":"2019070511331770000_pkz033-B17","article-title":"PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. Presented at the American Society of Clinical Oncology Annual Meeting, June 2018","volume":"36(15 suppl)","author":"Earl","year":"2018","journal-title":"J Clin Oncol"},{"key":"2019070511331770000_pkz033-B18","author":"Pivot"},{"issue":"24","key":"2019070511331770000_pkz033-B19","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1200\/JCO.2015.60.8620","article-title":"Efficacy of Adjuvant trastuzumab for patients with human epidermal growth factor receptor 2-positive early breast cancer and tumors \u2264 2 cm: a meta-analysis of the randomized trastuzumab trials","volume":"33","author":"O'Sullivan","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019070511331770000_pkz033-B20","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/annonc\/mdu177","article-title":"Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial","volume":"25","author":"Kramar","year":"2014","journal-title":"Ann Oncol"},{"issue":"9712","key":"2019070511331770000_pkz033-B21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","article-title":"Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"2019070511331770000_pkz033-B22","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"7305","key":"2019070511331770000_pkz033-B23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/bmj.323.7305.157","article-title":"Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests","volume":"323","author":"Deeks","year":"2001","journal-title":"BMJ"},{"key":"2019070511331770000_pkz033-B24","author":"Higgins","year":"2011"},{"issue":"9","key":"2019070511331770000_pkz033-B25","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat Med"},{"issue":"1","key":"2019070511331770000_pkz033-B26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jrsm.1211","article-title":"Neither fixed nor random: weighted least squares meta-regression","volume":"8","author":"Stanley","year":"2017","journal-title":"Res Synth Methods"},{"issue":"13","key":"2019070511331770000_pkz033-B27","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.ejca.2015.05.028","article-title":"Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study","volume":"51","author":"Pivot","year":"2015","journal-title":"Eur J Cancer"},{"issue":"12","key":"2019070511331770000_pkz033-B28","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/bjc.2016.357","article-title":"Trastuzumab-associated cardiac events in the Persephone trial","volume":"115","author":"Earl","year":"2016","journal-title":"Br J Cancer"},{"issue":"12","key":"2019070511331770000_pkz033-B29","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/bjc.2015.405","article-title":"Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198)","volume":"113","author":"Schneider","year":"2015","journal-title":"Br J Cancer"},{"issue":"5","key":"2019070511331770000_pkz033-B30","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1055\/s-0038-1633900","article-title":"Some problems with the investigation of noninferiority in meta-analysis","volume":"43","author":"Witte","year":"2004","journal-title":"Methods Inf Med"},{"issue":"2","key":"2019070511331770000_pkz033-B31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1406281","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer","volume":"372","author":"Tolaney","year":"2015","journal-title":"N Engl J Med"},{"issue":"suppl 8","key":"2019070511331770000_pkz033-B32","article-title":"191PD_PR 9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk\/benefit ratio","volume":"29","author":"Conte","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"2019070511331770000_pkz033-B33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10549-018-5001-x","article-title":"One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: systemic review and meta-anlsysis","volume":"173","author":"Inno","year":"2019","journal-title":"Breast Cancer Res Treat"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkz033\/28600851\/pkz033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jncics\/article-pdf\/3\/2\/pkz033\/28907965\/pkz033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T02:08:23Z","timestamp":1607479703000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkz033\/5488186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,11]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,5,11]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkz033","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6]]},"published":{"date-parts":[[2019,5,11]]},"article-number":"pkz033"}}